{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:11:57Z","timestamp":1791389517572,"version":"4.3.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04035-y","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T09:48:46Z","timestamp":1740476926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Switching JAK inhibitors: evaluating baricitinib\u2019s effectiveness in alopecia areata after tofacitinib failure"],"prefix":"10.1007","volume":"317","author":[{"given":"Ala","family":"Ehsani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Rahimnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhoushang","family":"Ehsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Aryanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanie","family":"Babaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"4035_CR1","unstructured":"Lepe K, Syed HA, Zito PM (2024) Alopecia areata. StatPearls. Treasure Island (FL)"},{"issue":"3","key":"4035_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","volume":"61","author":"C Zhou","year":"2021","unstructured":"Zhou C et al (2021) Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol 61(3):403\u2013423","journal-title":"Clin Rev Allergy Immunol"},{"key":"4035_CR3","doi-asserted-by":"crossref","unstructured":"\u0160uti\u0107 Udovi\u0107 I et al (2024) Deciphering the complex Immunopathogenesis of alopecia areata. Int J Mol Sci 25(11)","DOI":"10.3390\/ijms25115652"},{"issue":"5","key":"4035_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.25259\/IJDVL_975_19","volume":"87","author":"DA Yu","year":"2021","unstructured":"Yu DA et al (2021) Treatment outcome of oral Tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis. Indian J Dermatol Venereol Leprol 87(5):621\u2013627","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"4035_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jdv.15937","volume":"34","author":"L Guo","year":"2020","unstructured":"Guo L et al (2020) Benefit and risk profile of Tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol 34(1):192\u2013201","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4035_CR6","doi-asserted-by":"crossref","unstructured":"Faria S, Freitas E, Torres T (2023) Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date. Drugs Context 12","DOI":"10.7573\/dic.2023-6-2"},{"issue":"6","key":"4035_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40257-023-00808-1","volume":"24","author":"D Dahabreh","year":"2023","unstructured":"Dahabreh D et al (2023) Alopecia areata: current treatments and new directions. Am J Clin Dermatol 24(6):895\u2013912","journal-title":"Am J Clin Dermatol"},{"key":"4035_CR8","doi-asserted-by":"publisher","first-page":"1152513","DOI":"10.3389\/fimmu.2023.1152513","volume":"14","author":"D Wei","year":"2023","unstructured":"Wei D et al (2023) Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis. Front Immunol 14:1152513","journal-title":"Front Immunol"},{"issue":"5","key":"4035_CR9","doi-asserted-by":"publisher","first-page":"e15062","DOI":"10.1111\/dth.15062","volume":"34","author":"D Peterson","year":"2021","unstructured":"Peterson D, Powell M, King B (2021) Less is more? Failure of one JAK inhibitor does not predict failure of another one in a patient with alopecia areata. Dermatol Ther 34(5):e15062","journal-title":"Dermatol Ther"},{"issue":"6","key":"4035_CR10","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jaad.2023.03.041","volume":"89","author":"A Kazmi","year":"2023","unstructured":"Kazmi A et al (2023) Switching between Tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol 89(6):1248\u20131250","journal-title":"J Am Acad Dermatol"},{"key":"4035_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdcr.2023.11.001","volume":"43","author":"O Katamanin","year":"2024","unstructured":"Katamanin O, Ch\u2019 PYen, and, Song EJ (2024) Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy. JAAD Case Rep 43:36\u201339","journal-title":"JAAD Case Rep"},{"issue":"1","key":"4035_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi A et al (2021) Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review. J Am Acad Dermatol 85(1):162\u2013175","journal-title":"J Am Acad Dermatol"},{"key":"4035_CR13","doi-asserted-by":"publisher","first-page":"1054898","DOI":"10.3389\/fmed.2022.1054898","volume":"9","author":"M van Dalen","year":"2022","unstructured":"van Dalen M et al (2022) Anxiety, depression, and quality of life in children and adults with alopecia areata: A systematic review and meta-analysis. Front Med (Lausanne) 9:1054898","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"4035_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1515\/ijamh-2020-0100","volume":"34","author":"\u00d6 A\u015fk\u0131n","year":"2022","unstructured":"A\u015fk\u0131n \u00d6, Koyuncu Z, Serdaro\u011flu S (2022) Association of alopecia with self-esteem in children and adolescents. Int J Adolesc Med Health 34(5):315\u2013318","journal-title":"Int J Adolesc Med Health"},{"issue":"5","key":"4035_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","volume":"33","author":"K Phan","year":"2019","unstructured":"Phan K, Sebaratnam DF (2019) JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 33(5):850\u2013856","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"4035_CR16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jaad.2018.08.040","volume":"80","author":"LY Liu","year":"2019","unstructured":"Liu LY, King BA (2019) Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol 80(2):566\u2013568","journal-title":"J Am Acad Dermatol"},{"key":"4035_CR17","doi-asserted-by":"crossref","unstructured":"Zhao, M., et al. (2025) Baricitinib therapy for paediatric patients with severe alopecia areata. J Eur Acad Dermatol Venereol 39(1): p. e82\u2013e83.","DOI":"10.1111\/jdv.20108"},{"issue":"2","key":"4035_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/15569527.2022.2084622","volume":"41","author":"A Bandeira","year":"2022","unstructured":"Bandeira A, Albino-Teixeira A, Magina S (2022) Systematic review - alopecia areata and Tofacitinib in paediatric patients. Cutan Ocul Toxicol 41(2):194\u2013201","journal-title":"Cutan Ocul Toxicol"},{"issue":"2","key":"4035_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/bjd\/ljad118","volume":"189","author":"L Asfour","year":"2023","unstructured":"Asfour L et al (2023) Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib. Br J Dermatol 189(2):248\u2013250","journal-title":"Br J Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04035-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04035-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04035-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T09:48:49Z","timestamp":1740476929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04035-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4035"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04035-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received formal approval from the Ethics Committee of TUMS and the Razi Hospital Research Institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The requirement for informed consent to participate has been waived by the Ethics Committee due to retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"491"}}